Blood and Blood Components Market Report 2026

The blood and blood components market size has grown strongly in recent years. It will grow from $43 billion in 2025 to $45.38 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing prevalence of chronic blood disorders, expansion of trauma and emergency care services, rising adoption of component therapy, improvements in blood separation technologies, growth of hospital transfusion services.

The blood and blood components market size is expected to see steady growth in the next few years. It will grow to $55.16 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing demand for personalized transfusion medicine, rising investments in advanced storage technologies, expansion of oncology and hematology treatments, growing adoption of pathogen reduction technologies, increasing focus on minimizing blood wastage. Major trends in the forecast period include increasing demand for component-specific transfusions, rising adoption of automated blood component separation, growing use of platelet and plasma therapies, expansion of advanced blood storage solutions, enhanced focus on inventory optimization.

The increasing prevalence of bleeding disorders is anticipated to drive the growth of the blood and blood components market in the coming years. Bleeding disorders, including hemophilia, are medical conditions characterized by impaired blood clotting, which can result in excessive or prolonged bleeding, even from minor injuries or spontaneously. Blood and blood components play a vital role in treating these disorders, as they provide essential elements such as red blood cells, platelets, and clotting factors, which can be transfused to replace or supplement the deficient or dysfunctional components in patients, enhancing their clotting ability and overall health. For example, in July 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that hemophilia A occurs in approximately one in 5,000 male births in the United States, with around 400 babies born with hemophilia A each year. Furthermore, the current number of males living with hemophilia in the United States is estimated to be between 30,000 and 33,000. Consequently, the rising prevalence of bleeding disorders is fueling the growth of the blood and blood components market.

Major companies in the blood and blood component market are concentrating on developing advanced technologies, such as a precision blood typing process, to minimize complications during blood transfusions. Precision blood typing is a specialized method that employs sophisticated techniques to accurately identify an individual's blood type, including specific blood groups and subgroups, ensuring safe and correct transfusion of blood or blood products. For example, in April 2023, San Diego Blood Bank, a US-based blood bank, launched its precision blood initiative, designed to enhance the standard of care for blood transfusion patients by implementing the precision blood typing process. The program seeks to save lives and improve patient outcomes by elevating the quality of care during transfusions.

In December 2024, GC Biopharma Corp., a South Korea-based biopharmaceutical company, acquired ABO Holdings, Inc., for an undisclosed amount. Through this acquisition, GC Biopharma enhances its vertically integrated plasma-supply capabilities and supports the growth of its immunoglobulin business in the United States. ABO Holdings, Inc. is a US-based operator of plasma collection centers that provide source plasma, a vital blood component used in plasma-derived therapies.

Major companies operating in the blood and blood components market are American Red Cross, The Japanese Red Cross Society, Canadian Blood Services, Australian Red Cross, Vitalant, SANQUIN BLOOD SUPPLY FOUNDATION, New York Blood Center, Blood Bank of Alaska, Blood Centers of America, Xinjiang Deyuan Bioengineering, Harbin Pacific Biopharmaceutical, Southern Shuanglin Bio-Pharmacy, Beijing Tiantan Biological Products, Shanghai RAAS Blood Products, China Biologic Products, Hualan Biological Engineering, Biotest AG, Lorne Laboratories UK, LMB Germany, Bio Products Laboratory Ltd, Kedrion Biopharma, Hemanext Inc., Cellphire Inc., CSL Behring, Octapharma Canada Inc., Grifols.

North America was the largest region in the blood and blood components market in 2025. Western Europe was the second largest region in the global blood and blood components market analysis. The regions covered in the blood and blood components market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood and blood components market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the blood and blood components market by increasing costs of imported centrifuges, separation systems, storage freezers, testing reagents, and consumables used in component preparation. Hospitals and transfusion centers in North America and Europe are most affected due to dependence on imported equipment, while Asia-Pacific faces higher costs in scaling component processing facilities. These tariffs are increasing capital expenditure and operational costs. However, they are also promoting domestic production of blood processing equipment, regional reagent manufacturing, and improved supply chain resilience.

The blood and blood components market research report is one of a series of new reports that provides blood and blood components market statistics, including blood and blood components industry global market size, regional shares, competitors with a blood and blood components market share, detailed blood and blood components market segments, market trends and opportunities, and any further data you may need to thrive in the blood and blood components industry. This blood and blood components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood and its components refer to the various elements of blood, including red blood cells, white blood cells, platelets, and plasma, which are separated for medical use. These components are used to treat conditions such as anemia, clotting disorders, and immune deficiencies. Each component is transfused based on the patient’s specific needs for recovery.

The main types of products in blood and its components are whole blood and its individual parts. Human blood collected from a standard donation is known as whole blood. It is used for managing excessive bleeding, exchange transfusions, and autologous blood donation. The different blood components include red blood cells, platelets, plasma, and white blood cells, which are applied in treating anemia, trauma and surgical cases, cancer therapy, and bleeding disorders. The primary end-users include hospitals, ambulatory surgical centers, and other healthcare facilities.

The blood and blood components market consists of sales of red cells, platelets, plasms, cryoprecipitated AHF, and granulocytes. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.